Introduction: Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD). This review covers the pillars of care essential for the management of diabetic kidney disease (DKD) including (1) early diagnosis, (2) improved glycaemic control, (3) treatment of hypertension, (4) identification and treatment of associated metabolic bone disease and (5) identification and effective management of dyslipidaemia and additional cardiovascular risk factors.
Introduction
Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD) in the UK and is thought to be responsible for 50% of cases of endstage renal failure (ESRF) in the developed world. 1 Populations affected by the obesity epidemic are at increased risk of developing type 2 diabetes (T2D) and consequently at risk of CKD, from both obesity and DM, which progresses to ESRF. Worldwide, diabetes affects 422 million people. 2 In the UK, 3.6 million people are affected and~42.3% of patients with T2D and 32.4% of patients with T1D have CKD. 3, 4 This expanding patient population is concerning as this has the potential to overwhelm limited specialist resources, as well as primary care resources. CKD is concerning as it leads to increased morbidity and mortality, most commonly through premature cardiovascular disease. Early detection and appropriate management of diabetes and cardiovascular risk factors are essential to reduce morbidity and mortality. Focus needs to be directed towards (1) early diagnosis, (2) improved glycaemic control, (3) treatment of hypertension and the use of renin angiotensin aldosterone system inhibitors, (4) identification and treatment of associated metabolic bone disease, (5) identification and effective management of dyslipidaemia and additional cardiovascular risk factors such as consideration of anti-platelet agents and smoking cessation advice and (6) treatment of obesity.
Defining and diagnosing diabetic kidney disease
The terms diabetic nephropathy (DN) and diabetic kidney disease (DKD) are often used interchangeably. DN is the classic term used for disease caused by hyperglycaemia affecting the glomerulus. DKD can be thought of as an umbrella term, a more generic and widely encompassing term that includes disease outside the glomerulus. It is increasingly recognized that extra-glomerular lesions are seen in DKD, particularly tubulointerstitial lesions such as tubular atrophy, interstitial inflammation and tubulointerstitial fibrosis. In addition, renal artery stenosis, ischaemic nephropathy and cholesterol emboli syndrome may occur in a patient with diabetes. However, the classic changes that occur in DN are still relevant in patients with poorly controlled diabetes and hyperglycaemia. Increased glucose leads to increased glycolysis and the production of metabolites which are channelled through a number of pathways leading to increased oxidative stress, inflammation and fibrosis.
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The textbook definition of DKD is the presence of the triad of albuminuria (Table 1) , hypertension and declining renal function in people with diabetes. 5 However, not all patients with DKD have albuminuria. 4, 6 In cases where the disease is predominantly outside the glomerulus, e.g. in the interstitium, albuminuria may not be present. The UK National Diabetes Audit (NDA) revealed that 54.5% of patients with T1D and 63.7% of patients with T2D had an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 with a normal urine albumin creatinine ratio (urine ACR). 4 This survey only uses one measurement of eGFR or urine ACR to diagnose CKD whereas the definition of CKD is based on at least two readings to suggest chronic rather than acute disease. 7 Nevertheless, it demonstrates that a significant number of patients have DKD without albuminuria. In DKD, diabetes may be the perpetrator (directly causing CKD), the co-conspirator or, the innocent bystander. A retrospective study looking at individuals with T2D and DKD found that 62% had isolated diabetic nephropathy, 36% had hypertensive nephropathy, glomerulonephritides or acute tubular necrosis and the remainder had a combination of diabetes and non-diabetes related causes. 6 In the same way in which DKD can present without proteinuria, it is possible that CKD with proteinuria is not caused by diabetic nephropathy and it is also important to exclude non-diabetes related conditions that also cause proteinuria such as myeloma related kidney disease. Alternate causes of CKD should be excluded in the following circumstances:
(1) A rapid decline in the glomerular filtration rate (GFR) (2) Rapidly increasing proteinuria or nephrotic syndrome (3) The presence of refractory hypertension (4) The presence of an active urinary sediment (unexplained microscopic haematuria) (5) Signs and symptoms of systemic disease, e.g.
suggestive of a vasculitis (6) >30% reduction in GFR following the initiation of angiotensin receptor blockers (ARB)/ angiotensin converting enzyme inhibitors (ACEI) suggestive of renovascular disease (7) In the absence of diabetic retinopathy. 1 [NB whilst retinopathy and DKD often co-exist, diabetic retinopathy is not always seen (up to 40% of patients with DKD do not have retinopathy), however, the presence of retinopathy predicts more rapid progression of DKD.] 8, 9 CKD is diagnosed by measuring a reduced eGFR and/or elevated urine ACR on at least two occasions over 90 days. Whilst not all patients with DKD have albuminuria, it is still important to monitor for this as it is an early modifiable risk factor for DKD. It is not clear if albuminuria is simply a marker of disease or whether the albuminuria itself is nephrotoxic, through causing a sclerosing reaction as the albumin passes through the nephron.
The inconvenience and inaccuracy of 24 h urine collections to measure albuminuria have led to the use of first morning void samples for urine ACR. These vary according to diet (consumption of meat), exercise and temperature. Thus the intraindividual coefficient of variation of urine ACR is high >50%.
7 Urine ACR has greater sensitivity compared to protein creatinine ratio (PCR) at lower levels of proteinuria and urine ACR is the recommended investigation for people with diabetes. 10 The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that urine ACR > 2.5 mg/mmol in men and >3.5 mg/mmol in women are abnormal. The terms microalbuminuria and macroalbuminuria have now been replaced by a KDIGO grading of mild, moderate and severe albuminuria (Table 1 ). However, in many current papers the older terms are still used.
GFR is estimated using equations such as the Modification of Diet in Renal Disease equation; this takes age, gender and ethnicity into account. Several factors interfere with the accuracy of this measurement including: obesity, excess muscle mass (body builders), reduced muscle mass (muscle wasting disorders, amputations) and meat consumption. The Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) formula may be more valid in DKD. 10 Creatinine clearance can be used where eGFR is thought to underestimate renal function. This is determined by a 24 h urine collection with a concomitant measurement of serum creatinine. However, errors in urine collection (under-collection) will underestimate GFR and vice versa. In addition, as creatinine is secreted in the proximal tubule, creatinine clearance can overestimate GFR in more severe disease. More accurate determination of GFR can be achieved by measuring the clearance of an exogenous substance such as inulin. Cystatin C, a cysteine protease inhibitor, may also be an accurate marker of GFR; however, this is not currently widely available.
There has been progress in the study of novel biomarkers to detect early stages of CKD (i.e. disease not identified by a change in eGFR or the presence of albuminuria). Biomarkers for oxidative stress, glomerular damage, tubular damage and renal inflammation are at varying stages of development and may have a role in the future. 11 Currently, these are not widely available and the cost would be prohibitive given the large numbers of people with diabetes requiring screening. There is however, a valid role for alternate biomarkers, for example, in patients where renal biopsy should be avoided. 12 The pathogenesis of DKD as described above focuses around excess glucose triggering various pathways and so it is logical that reduction in glucose leads to improved glomerular function. These studies (DCCT-EDIC, UKPDS, ADVANCE) did not demonstrate that intensifying glucose control led to reduction in the rate of cardiovascular events. In fact a U-shaped relationship between glycaemic control and mortality has been shown. As clearance falls, the risk of hypoglycaemia and hypoglycaemic unawareness increases. Low HbA1c (<48 mmol/mol) has been associated with increased risk of premature death. The ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) showed increased mortality in the intensively treated arm. 12 In this study, rates of hypoglycaemia were twice as high in patients with CKD compared to patients without CKD. Achieving tight control therefore should not be achieved at the cost of excess hypoglycaemic events. Various oral hypoglycaemic agents should be limited or restricted at lower eGFR as renal impairment affects the pharmacokinetics of these agents ( Table 2) . HbA1c is a measurement of glycated haemoglobin. It is therefore affected by disease that causes disturbance of the red blood cell lifespan such as anaemia in renal disease or haemodialysis. Fructosamine (predominantly a measure of glycated albumin) has been proposed as a measure of glycaemic control. This reflects glycaemic control over a period of 1-3 weeks. Measurement of this may be inaccurate in the context of abnormal protein metabolism (e.g. in nephrotic syndrome). Therefore, in DKD, blood glucose profiles may be more accurate and interpretable.
Glycaemic control
NICE guidelines for T1D and T2D advise an individualized HbA1c target. This depends on the type of diabetes, the risk of hypoglycaemia, the stage of CKD and whether or not the patient is on dialysis. The studies which demonstrated benefits of a low HbA1c on microvascular outcomes were largely conducted in individuals without CKD at the trial onset (e.g. DCCT, UKPDS). However, these studies also demonstrated a legacy effect of intensive initial control which had an impact on the onset and severity of DKD. Therefore a strategy of more intense initial control in younger patients with less severe DKD and more relaxed control for patients in ESRF may be pragmatic and effective. Current recommendations for patients on dialysis are to aim for a target HbA1c between 58 and 68 mmol/mol. 13 Alternate targets are recommended for younger patients and for patients with less severe DKD ( Table 3 ).
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The older anti-hyperglycaemic agents have been extensively reviewed previously. 5 Therefore, we have focused attention on the newer anti-hyperglycaemic agents, sodium and glucose co-transporter 2 (SGLT-2) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists, which have been shown to reduce the rate of major cardiovascular events and DKD.
Sodium glucose co-transporter 2 (SGLT-2) inhibitors
SGLT-2 inhibitors were licenced in Europe in 2012 and these are the newest commonly used treatment for T2D. These block the reabsorption of both sodium and glucose at the proximal renal tubule. These deserve attention as it is possible that they reduce the progression of DKD through a mechanism independent of the improvement in glycaemia. The possible mechanism of their effect on DKD is thought to be due to the actions on natriuresis and contraction in plasma volume which contribute to the anti-hypertensive effect. It has been proposed that by blocking sodium reabsorption in the proximal tubule, more sodium is delivered and passes across the macula densa and juxtaglomerular apparatus and this leads to constriction of the The EMPA-REG OUTCOME study was a randomized, double blind, placebo controlled trial in patients over the age of 18 years with T2D and established cardiovascular disease. A sub-analysis of this trial demonstrated positive effects on DKD. Empagliflozin led to a lasting reduction in urine ACR which was most significant in patients with KDIGO A3 albuminuria (previously described as macroalbuminuria). In this study, eGFR initially decreased until week 4 (likely to the reduced hyperfiltration) but then increased and stabilized. 17 Most patients in this trial were already established on RAAS inhibitors so the renal effects of empagliflozin were additive and not associated with additional adverse effects, as described below with dual RAAS blockage. The Canagliflozin Cardiovascular Assessment Study (CANVAS) also demonstrated a reduction in nephropathy with reduced progression of albuminuria, reduced deterioration in eGFR and reduced requirement for renal replacement therapy or death from renal causes. 18 Of note, these were secondary outcomes in these studies and dedicated outcome trials in CKD are yet to be reported CREDENCE (empagliflozin) and DAPA-CKD. Canagliflozin has been associated with an increased risk of amputation (CANVAS) however, the mechanism of this is not yet understood and it is not clear if this is a class effect as there were no similar findings in the EMPA-REG OUTCOME study. 18 Unfortunately, patients with CKD are at high risk of diabetic foot disease and amputation and this may limit the use of this drug in this vulnerable population until this association is clarified and the mechanism understood. 
Glucagon like peptide-1 (GLP-1) receptor agonists

Management of glycaemia in patients having dialysis
The management of hyperglycaemia in patients on dialysis (peritoneal or haemodialysis) is complicated by additional factors including the composition of the dialysate. Most patients on haemodialysis are manged with insulin therapy. The starting dose often needs to be reduced by 25% due to reduced insulin clearance. For patients on peritoneal dialysis, intraperitoneal insulin is not recommended as higher doses of insulin are often required and the timing of the dose is more difficult to manage. There is also the potential risk of bacterial contamination of the dialysate. If patients only have mild hyperglycaemia then it is possible that they can be managed with DPP-IV inhibitors or meglitinides at a low starting dose. Metformin, sulphonylureas, pioglitazone, acarbose, SGLT-2 inhibitors and GLP-1 receptor agonists are not licensed for use in haemodialysis and are not recommended in this context. 
Renin-angiotensin aldosterone system (RAAS) antagonists
ACEI and ARB are both renoprotective in T1D and T2D and for the past two decades these have been the most effective treatment for DKD. As well as lowering blood pressure they also reduce urinary albumin excretion. ACEI cause a selective vasodilation of the efferent arterioles (through a reduction in angiotensin II), this reduces intraglomerular hypertension. Therefore, it is usual to see a drop in eGFR on starting treatment. If the drop is <25% the drug can be continued but urea and electrolytes should be rechecked. If the drop is >25% then the drug should be stopped and other causes of deterioration should be explored e.g. concomitant use of nephrotoxic drugs, dehydration or acute illness. It is also important to monitor for hyperkalaemia. If the pre-treatment potassium is >5 mmol/l then RAAS agents may be contra-indicated and they should be reduced or stopped if the levels increase to 6 mmol/l.
Initially, it was thought that dual RAAS blockade would be more effective. However, three trials (ONTARGET, ALTITUDE and VA-NEPHRON D) demonstrated adverse effects including: hyperkalaemia, acute kidney injury and lack of effect. 12 In addition, aliskiren, a direct renin inhibitor, was found to be associated with increased adverse events in the ALTITUDE study in T2D.
Nondihydropyridine calcium channel blockers, e.g. diltiazem have been shown to slow the rate of progression of DKD in experimental studies and small clinical trials. 22 These effects are not seen with the dihydropyridine calcium channel blockers such as amlodipine which have variable effects on albumin excretion. Of note, diltiazem alone was associated with tubulointerstitial fibrosis and global glomerulosclerosis. However, combination of diltiazem and an ACEI negated these effects. Mineralocorticoid receptor blockade is effective and associated with a reduction in albuminuria. In short term trials, spironolactone led to a reduction in 24 h urine albumin excretion, however, the side effect of hyperkalaemia limits the use of this in combination with RAAS blockade. 23 1, 25-dihydroxyvitamin D negatively regulates renin therefore may have a protective role in DKD. VITAL (selective VITamin D receptor activator for albuminuria lowering) demonstrated a reduction in urine albumin excretion by 18% and additional clinical trials are in progressive to assess the efficacy of this therapy. 23 Endothelins regulate BP through vascular tone and through natriuresis. Endothelin-1 (similar to angiotensin II) is a potent vasoconstrictor of the efferent arteriole. Overexpression of endothelins is associated with glomerulosclerosis and tubulointerstitial fibrosis. The ASCEND trial, looking at avosentan, an ET A R antagonist, demonstrated a reduction in albuminuria, however, was associated with an excess of cardiovascular disease.
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Bone protection
New clinical guidelines advise monitoring of calcium, phosphate, parathyroid hormone (PTH) and vitamin D levels at CKD stage 3. 24 However, secondary hyperparathyroidism, a common complication of CKD associated with increased risk of fractures and mortality, may be present at an early stage of CKD. Previous indicators of secondary hyperparathyroidism such as a high serum phosphate have been superseded by other markers which are present earlier in the disease, such as fibroblast growth factor 23 (FGF23) however, these are not widely available in clinical practice. FGF23 levels increase in CKD stage 2 when calcium, phosphate and PTH are still within the normal range. FGF23 is a phosphaturic hormone released by osteocytes and osteoblasts which also leads to a reduction in active vitamin D. These maintain the phosphate level until their function is overwhelmed. Briefly, FGF23 binds to its co-receptor Klotho in the distal tubule, this down-regulates the sodium phosphate co-transporter in the proximal tubule thus reducing phosphate reabsorption and promoting phosphate excretion. 25 Persistent stimulation of the parathyroid gland by elevated phosphate, low calcium and reduced 1,25-(OH) 2 vitamin D leads to diffuse (polyclonal) hyperplasia which later transforms to nodular (monoclonal) hyperplasia. 25 Monitoring the trend in PTH is helpful as there is a high intra-individual variation. KDIGO guidelines for dialysis patients are to maintain PTH within 2-9 times the upper limit of normal. However, guidelines for predialysis patients are not agreed. 24 In both dialysis and non-dialysis patients, if the PTH remains persistently elevated then modifiable risk factors such as elevated phosphate, hypocalcaemia and vitamin D deficiency should be treated. Persistent elevated phosphate levels can be treated by diet (phosphate restriction), dialysis or phosphate binders. Vitamin D deficiency should be corrected using the guidelines for the general population. Calcitriol and vitamin D analogues are now no longer recommended for patients who not on dialysis based on their lack of efficacy on cardiovascular outcomes and it is advised that these are reserved for patients with severe or progressive secondary hyperparathyroidism. 24 
Lipids
In non-dialysis dependent CKD, cardiovascular events are reduced by statins and ezetimibe. The KDIGO and ABCD-RA guidelines recommend statins in non-dialysis dependent CKD. 26, 27 In patients with T1D, statin initiation is recommended for patients with DKD >30 years or younger (18-30 years) if they have additional cardiovascular risk factors. In T2D, statin initiation is recommended in all patients with DKD. 27 However, in patients on dialysis there has been a failure to demonstrate a similar reduction in cardiovascular events or any survival advantage, e.g. the Die Deutsche Diabetes Dialyse Studie (4D). 28 Therefore, the KDIGO guidelines suggest that statins are not initiated in patients on dialysis; however, if patients are already on statins, these do not necessarily need to be discontinued. 26 The reason for the lack of efficacy of statins in patients on haemodialysis may reflect a difference in pathology of cardiovascular disease with vascular calcification and less easily reversible arteriosclerosis. The question about whether or not statins affect the progression of DKD is controversial. Hyperlipidaemia is a potential cause of kidney disease though lipotoxicity of intra-renal atherosclerosis. In theory, statins should improve progression in disease; however, conflicting results are seen in practice. The Collaborative Atorvastatin Diabetes Study (CARDS) showed that atorvastatin improved eGFR but not albuminuria. 28 However, the SHARP study did not show any reduction in the rate of decline of eGFR or progression to ESRF. A meta-analysis found that statins were associated with a reduction in albuminuria in patients with T2D but not in T1D if the patients already had albuminuria at baseline. Most studies failed to demonstrate a significant improvement in eGFR.
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Diet
Patients with DKD may require low salt and potassium diets. Low salt diets (<5 g sodium chloride/ day) have been shown to reduce blood pressure and have additional benefits on the effectiveness of RAAS inhibition. 12, 26 Low K + diets are often necessary in patients on RAAS blockage. In the past, it was felt that low protein diets would reduce the protein burden on kidneys leading to reduced proteinuria and improved GFR. However, trials of these diets have led to variable clinical findings and these are no longer advocated.
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Weight loss
Obesity is often related to T2D and it is an independent risk factor for CKD leading to focal segmental glomerulosclerosis. 30 In addition, obesity is increasingly seen amongst patients with T1D, reflecting population trends. Weight loss is associated with a reduction in proteinuria. 31 Bariatric surgery is the most successful treatment of obesity and has been shown to cause remission of diabetes and reduction in CKD and albuminuria. 32, 33 The various different types of bariatric surgery have different efficacies. For example, a Roux-en-Y gastric bypass (RYBG) leads to more sustained weight loss compared to a gastric band. The effects of bariatric surgery can be summarized through the BRAVE acronym (bile flow alteration, restriction of stomach size, altered nutrient flow, vagal manipulation and enteral (gut) hormone manipulation). Whilst bariatric surgery has numerous benefits including remission of diabetes, reduction of hypertension and reduced glomerular hyperfiltration there are associated risks with a peri-operative mortality of 0.1-0.2%. In addition, RYGB and biliopancreatic diversion with duodenal switch (BPD/DS) are both associated with altered oxalate and citrate excretion and oxalate nephropathy may develop, which in itself may lead to ESRF.
Pancreas transplantation
There There are several options for transplantation: simultaneous pancreas kidney transplant (SPK), pancreas after kidney transplant (PAK) and pancreas transplantation alone (PTA). Over the years success rates for pancreas transplantation have improved, due to increased technical success and also improved immunosuppressive regimes. Currently 5 year patient and graft mortality are highest for SPK, followed by PAK with PTA being less successful and less common. 34 Currently concerns about decline in renal function with calcineurin inhibitors, the risk of long-term infections complications and the risk of long-term haematological malignancy limit the utility of pancreas transplantation for the majority of patients with diabetes. Islet cell transplantation has not been as successful as whole organ transplantation. Islet cell transplants have a 5-year insulin independence rate of 11%0. 34 New onset diabetes after transplantation (NODAT) occurs in 15-25% of cases. This is associated with steroids and with calcineurin inhibitors, especially tacrolimus. These drugs lead to pancreatic cell apoptosis leading to reduced insulin production. They also interfere with skeletal muscle glucose uptake. NODAT may reduce the longevity of the transplanted organ and also leads to increased risk of cardiovascular disease.
Anaemia
Patients with diabetes develop anaemia at a younger age and with greater severity compared to patients without diabetes. One in five patients with diabetes have anaemia; the causes of which include: deteriorating renal function, erythropoietin deficiency or resistance, chronic inflammation, nutritional deficiencies, iron deficiency, gastrointestinal bleeding and infectious disease. Patients with anaemia have higher levels of microvascular and macrovascular complications and anaemia is an independent risk factor for cardiovascular disease. Anaemia has also been shown to increase risk of progression of DKD, possibly through reduced oxygen delivery and heart failure.
Treatment of anaemia with iron replacement and erythropoietin has been shown to improve quality of life but overtreatment leads to worsened cardiovascular outcomes, such as heart failure and ischaemic heart disease. Therefore the target for Hb suggested by NICE is between 100 and 120 g/l. 35 
Aspirin
The effectiveness of anti-platelet agents has already been established for the secondary prevention of cardiovascular disease. Patients with CKD are at higher risk of atherosclerosis, atrial fibrillation and increased risk of venous and arterial thromboembolic disease. 12 However, they also have a higher risk of bleeding. Steno-2, a study which used aspirin as a component of multiple risk reduction, found that this was effective in reducing cardiovascular risk; however, a meta-analysis of six studies failed to demonstrate the efficacy of aspirin. Therefore, JBS3 guidelines advise against using aspirin as primary prevention in patients with DKD. 36 The JBS3
guidelines have a caveat regarding the use of aspirin in patient with T1D with established nephropathy. However, in CKD in general, aspirin is not advocated for primary prevention based on the increased bleeding risk in CKD. 36 
Smoking
Smoking is an important modifiable and independent risk factor for cardiovascular disease. The rate of cardiovascular events tripled in smokers versus non-smokers in patients with DKD. 37 Therefore, patients should be offered smoking cessation advice and have access to smoking cessation clinics.
Referral to specialist renal care
Referral criteria to renal clinics were based on evidence demonstrating that early access to specialist care reduced morbidity, mortality and healthcare costs. 10, 38 The current proposed criteria include:
(1) GFR < 30 ml/min/ ) and a change in GFR category within 12 months. (5) Poorly controlled hypertension (using four agents) (6) Suspected renal artery stenosis If these guidelines were to be followed, this would expand the volume of outpatient referrals by over a third and secondary and tertiary centres currently do not have the capacity to meet these increased demands. 38 Enhanced primary care management using interactive technology and input from specialist services may help to help specialist services from becoming overwhelmed and in rationalizing limited resources.
Conclusions
Early diagnosis and prompt treatment of diabetes and associated cardiovascular risk factors such as hypertension and obesity is essential to limiting the progression of DKD. Despite the plethora of new molecular targets, such as endothelin inhibitors, few of these have translated in to tangible therapies for the practicing physician. However, GLP-1 agonists and SGLT-2 inhibitors show some promise with regards to limiting the progression of DKD. With this in mind and with the predicted increase in cases of DKD due to the obesity epidemic, the focus should include obesity management and also focus on the primary prevention of disease. Attention also needs to be given to the logistics of managing this increasing number of patients with DKD within primary and secondary care.
